Protara Therapeutics (TARA) Retained Earnings (2013 - 2026)
Protara Therapeutics (TARA) posted quarterly Retained Earnings of $501.7 million for Q1 2026, up 20.82% year-over-year from $415.2 million in Q1 2025, and up 557364.44% quarter-over-quarter from $90000.0 in Q4 2025.
Protara Therapeutics (TARA) Retained Earnings (2013 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Retained Earnings for 14 consecutive years, with $501.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 20.82% year-over-year to $501.7 million; the TTM figure through Mar 2026 stood at $501.7 million (up 20.82% YoY), while the FY2025 annual figure was $90000.0, down 99.98% from the prior year.
- Retained Earnings improved to $501.7 million in Q1 2026 per TARA's latest filing, from $90000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $501.7 million in Q1 2026 and bottomed at -$285.1 million in Q3 2025.
- Historically, Retained Earnings has averaged $60.2 million across 5 years, with a median of -$165000.0 in 2023.
- Annual changes were most pronounced in 2022 — Retained Earnings slumped 63782.32% — and 2024, when it surged 190373.94%.
- Protara Therapeutics' Retained Earnings stood at -$160.0 million in 2022, then decreased by 25.27% to -$200.4 million in 2023, then jumped by 305.64% to $412.1 million in 2024, then sank by 99.98% to $90000.0 in 2025, then jumped by 557364.44% to $501.7 million in 2026.
- Business Quant data shows TARA's Retained Earnings at $501.7 million in Q1 2026, $90000.0 in Q4 2025, and -$285.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - | 503.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 503.48 Mn |
| Mar 31, 2026 | 501.72 Mn |
| Dec 31, 2025 | 90,000.00 |
| Sep 30, 2025 | -285.11 Mn |
| Jun 30, 2025 | 77,000.00 |
| Mar 31, 2025 | 415.25 Mn |
| Dec 31, 2024 | 412.08 Mn |
| Sep 30, 2024 | 313.95 Mn |
| Jun 30, 2024 | -220.99 Mn |
| Mar 31, 2024 | 269.88 Mn |
| Dec 31, 2023 | -200.38 Mn |
| Sep 30, 2023 | -165,000.00 |
| Jun 30, 2023 | -180.30 Mn |
| Mar 31, 2023 | 264.24 Mn |
| Dec 31, 2022 | -159.96 Mn |
| Sep 30, 2022 | -1.13 Mn |
| Jun 30, 2022 | -1.12 Mn |
| Mar 31, 2022 | -104.77 Mn |
| Dec 31, 2021 | 256.13 Mn |
| Sep 30, 2021 | 254.22 Mn |